Effect of gynecological operations on the serum concentration of the aminoterminal propeptide of type III procollagen

References

• Liotta LA. Tumor invasion and metastases - role of extracellular matrix: Rhoads memorial award lecture. Cancer Res 1986; 46: 1–7
   PubMed Web of Science ®Google Scholar
• Van den Hooff AO. Connective tissue as an active participant in the process of malignant growth. Anticancer Res 1986; 6: 775–80
   PubMed Web of Science ®Google Scholar
• Dvorak HF. Tumors: wounds that do not heal - similarities between tumor stroma generation and wound healing. N Eng J Med 1986; 26: 1650–9
   Google Scholar
• Whalen GF. Solid tumours and wounds: transformed cells misunderstood as injured tissue. Lancet 1990; 336: 1489–92
   Google Scholar
• Haukipuro K, Risteli L, Kairaluoma MI, Risteli J. Amino-terminal propeptide of type III procollagen in serum during wound healing in human beings. Surgery 1990; 107: 381–8
   PubMed Web of Science ®Google Scholar
• Risteli J, Niemi S, Trivedi P, Maentausta O, Mowat AP, Risteli L. Rapid equilibrium radioimmunoassay for the amino-terminal propeptide of human type III procollagen. Clin Chem 1988; 34: 715–8
   PubMed Web of Science ®Google Scholar
• Risteli L, Risteli J. Noninvasive methods for detection of organ fibrosis. Connective Tissue in Health and Disease, M Rojkind. CRP Press, Boca Raton, Florida 1990; 61–98
   Google Scholar
• Trivedi P, Hindmarsh P, Risteli J, Risteli L, Mowat AP, Brook CG. Growth velocity, growth hormone therapy, and serum concentrations of the amino-terminal propeptide of type III procollagen. J Pediatr 1989; 114: 225–30
   PubMed Web of Science ®Google Scholar
• Risteli L, Puistola U, Hohtari H, Kauppila A, Risteli J. Collagen metabolism in normal and complicated pregnancy: changes in the aminoterminal propeptide of type III procollagen in serum. Eur J Clin Invest 1987; 17: 81–6
   PubMed Web of Science ®Google Scholar
• Risteli L, Risteli J, Puistola U, Tomas C, Zhu GG, Kauppila A. Aminoterminal propeptide of type III procollagen in ovarian cancer (a review). Acta Obstet Gynecol Scand 1992; 99–103, Supp. 155
   Google Scholar
• Hatahara T, Igarashi S, Funaki N. High concentrations of N-terminal peptide of type III procollagen in the sera of patients with various cancers with special reference to liver cancer. Gann 1984; 75: 130–5
   PubMedGoogle Scholar
• Puistola U, Risteli L, Risteli J, Kauppila A. Collagen metabolism in gynecological patients: Changes in the concentration of the aminoterminal propeptide of type III procollagen in serum. Am J Obstet Gynecol 1990; 163: 1276–81
   Google Scholar
• Kauppila A, Puistola U, Risteli J, Risteli L. Amino-terminal propeptide of type III procollagen: a new prognosis indicator in human ovarian cancer. Cancer Res 1989; 49: 1885–9
   PubMed Web of Science ®Google Scholar
• Tomas C, Penttinen J, Risteli J, Risteli L, Kauppila A. Simultaneous evaluation of epithelial cell function by CA125 and stromal cell activity by aminoterminal propeptide of type III procollagen (PIIINP) in ovarian carcinoma. Ann Med 1990; 22: 115–21
   PubMed Web of Science ®Google Scholar
• Tomas C, Penttinen J, Risteli J, Risteli L, Vuori J, Kauppila A. Serum concentrations of CA 125 and aminoterminal propeptide of type III procollagen (PIIINP) in patients with endometrial carcinoma. Cancer 1990; 66: 2399–406
   Google Scholar
• Tomas C, Risteli J, Risteli L, Vuori J, Kauppila A. Use of various epithelial tumor markers and stromal marker in the assessment of cervical carcinoma. Obstet Gynecol 1991; 77: 566–72
   Google Scholar
• Tomas C, Kauppila A. Clinical usefulness of epithelial and stromal tumor markers in vulvar carcinoma. Int J Gynecol Cancer 1992, submitted
   Google Scholar
• Haukipuro K, Risteli L, Kairaluoma MI, Risteli J. Aminoterminal propeptide of type III procollagen in healing wound in humans. Ann Surg 1987; 206: 752–6
   PubMed Web of Science ®Google Scholar
• Gay S, Viljanto A, Raekallio J, Penttinen R. Collagen types in early phases of wound healing in children. Acta Chir Scand 1978; 144: 205–11
   PubMedGoogle Scholar
• Fleck A, Myers MA. Diagnostic and prognostic significance of the acute-phase proteins. The acute-phase response to injury and infection, Koj Gordon. Elsevier Science Publishers B. V. (Biomedical Division). 1985; 249–71
   Google Scholar
• Colley CM, Fleck A, Goode AW, Muller BR, Myers MA. Early time course of the acute phase protein response in man. J Clin Pathol 1983; 36: 203–7
   PubMed Web of Science ®Google Scholar
• Roberts AB, Flanders KC, Kondaiah P. Transforming growth factor-beta: biochemistry and roles in embryogen-esis, tissue repair and remodelling, and carcinogenesis. Recent Prog Horm Res 1988; 44: 157–97
   PubMedGoogle Scholar
• Krummel TM, Michna BA, Thomas BL. Transforming growth factor beta (TGF-beta) induces fibrosis in a fetal wound model. J Pediatr Surg 1988; 23: 647–52
   PubMed Web of Science ®Google Scholar
• Jacobs I, Bast RC, Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod 1989; 4: 1–12
   PubMed Web of Science ®Google Scholar
• Halila H, Suikkari A-M, Seppala M. The effect of histerec-tomy on serum CA 125 levels in patients with adenomyosis and uterine fibroids. Human Reprod 1987; 2: 265–6
   Google Scholar
• Van der Zee AG, Duk JM, Aalders JG, Boontje AH, Ten Hoor KA, De Bruijn HW. The effect of abdominal surgery on the serum concentration of the tumour-associated antigen CA 125. Br J Obstet Gynaecol 1990; 97: 934–8
   PubMedGoogle Scholar
• Avall-Lundqvist E, Sjovall K, Hansson LO, Eneroth P. Peri- and postoperative changes in serum level of four tumor markers and three acute phase reactants in benign and malignant gynecological diseases. Arch Gynecol Obstet 1992; 251: 69–78
   Google Scholar
• Talbot RW, Jacobsen DJ, Nagorney DM, Malkasian GD, Ritts R EJ. Temporary elevation of CA 125 after abdominal surgical treatment for benign disease and cancer. Surg Gynecol Obstet 1989; 168: 407–12
   PubMedGoogle Scholar